Kernal Biologics
Cambridge, Massachusetts, United States · Biotechnology, Healthcare, Health Care
Kernal Bio is a venture-backed therapeutics company engineering cells inside the body using AI-designed, selective mRNA and targeted LNP technology. By developing in vivo CAR-T therapies, Kernal Bio is advancing precision treatments for autoimmune diseases and blood cancers. The company was founded by experts from MIT, Harvard, Merck, and BMS, and its leadership team brings a track record of three
Key facts
- Headquarters
- Cambridge, Massachusetts, United States
- Employees
- 15
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Private
- Website
- kernalbio.com
- Company page
Recent activity at Kernal Biologics
- : Kernal Biologics has been awarded $48 million from ARPA-H to develop in vivo CAR T-cell therapies for hematological cancers. This funding is part of ARPA-H’s EMBODY program, aimed at enhancing immune cell engineering.
- : Kernal Biologics Announces $25M Series A Financing To Advance Its Mrna 2.0 Technology For Oncology
- : Kernal Biologics, Inc.
- : Kernal Biologics, Inc.
- : Kernal Biologics, Inc.
Kernal Biologics funding history
| Date | Round | Amount |
|---|---|---|
| Oct 2025 | Funding Round | $48.0M |
| Jul 2022 | Series A | $25.0M |
| Feb 2022 | Venture | $20.1M |
| Aug 2018 | Venture | $500K |
| Sep 2016 | Venture | $350K |
Leadership
- Yusuf Erkul, Executive Officer, Director
- Burak Yilmaz, Executive Officer, Director
- Oguzhan Yilmas, Director
- Catherine Moroski, Executive Officer, Director
Verified email and direct lines for Kernal Biologics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Kernal Biologics files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Kernal Biologics in the news
- US government earmarks up to $48M for development of Kernal's mRNA CAR-T - Fierce Biotech (Oct 07, 2025)
- Kernal Biologics to Showcase mRNA 2.0 Platform and T-Cell-Targeted LNPs for In Situ CAR T Programming at ASGCT 2026 - BioSpace (Apr 30, 2026)
- Kernal Bio Joins Lilly Gateway Labs to Accelerate In Vivo Cell Therapies - Business Wire (Oct 03, 2025)
- Kernal gets $48M to develop easier, cheaper CAR T-cell therapies - Multiple Sclerosis News Today (Oct 14, 2025)
- Kernal Biologics Announces $25M Series A Financing to Advance its mRNA 2.0 Technology for Oncology - PR Newswire (Jul 07, 2022)
- Amgen-backed Kernal Biologics pops off with $25M for mRNA platform - Fierce Biotech (Jul 07, 2022)
- Kernal Bio Awarded up to $48 Million from ARPA-H to Develop Lower Cost in vivo CAR T-cell Therapies for Hematological Cancers and Autoimmune Disease - Business Wire (Oct 07, 2025)
Companies similar to Kernal Biologics
- Aarvik Therapeutics · Biotechnology, Healthcare, Health Care, research
- BioLineRx Ltd · Biotechnology, Healthcare, Health Care, research
- Galectin · Biotechnology, Healthcare, Health Care
- Akadeum Life Sciences · Biotechnology, Healthcare, Health Care
- Swarm Oncology Ltd · Biotechnology, Health Care, research
About Kernal Biologics: questions and answers
What does Kernal Biologics do?
Kernal Bio is a venture-backed therapeutics company engineering cells inside the body using AI-designed, selective mRNA and targeted LNP technology. By developing in vivo CAR-T therapies, Kernal Bio is advancing precision treatments for autoimmune diseases and blood cancers. The company was founded by experts from MIT, Harvard, Merck, and BMS, and its leadership team brings a track record of three
Where is Kernal Biologics headquartered?
Kernal Biologics is headquartered in Cambridge, Massachusetts, United States.
How many employees does Kernal Biologics have?
Kernal Biologics has about 15 employees.
Has Kernal Biologics raised funding?
Yes. Fundz has recorded 5 funding events for Kernal Biologics. The most recent, Funding Round of $48.0M, was in Oct 2025.
What is the latest news on Kernal Biologics?
On Oct 07, 2025, Kernal Biologics has been awarded $48 million from ARPA-H to develop in vivo CAR T-cell therapies for hematological cancers. This funding is part of ARPA-H’s EMBODY program, aimed at enhancing immune cell engineering.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy